Covaxin
A vial of Covaxin | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Trade names | Covaxin |
| Routes of administration | Intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
|
| COVID-19 portal |
Covaxin (development name, BBV152) is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.[2]
On 3 November 2021, the World Health Organization (WHO) validated the vaccine for emergency use, as the first Indian-developed covid vaccine to be approved.[3][4] By 31 January 2022, Covaxin had been granted emergency use approval in 13 countries.[5]
- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
- ^ Mitra AK, Singh S (3 November 2021). "India's first homegrown COVID-19 shot wins WHO emergency use listing". Reuters. Retrieved 8 November 2021.
- ^ "WHO issues emergency use listing for eighth COVID-19 vaccine". World Health Organization (WHO) (Press release). Retrieved 3 November 2021.
- ^ "Covaxin granted emergency use approval in 13 countries, Govt informs Parliament". India Today. Retrieved 4 February 2022.